Searched for
VALGANCICLOVIR
Zydus Lifesciences launches breakthrough drug for transplant patientsZydus Lifesciences introduces ANVIMO (Letermovir) for CMV prevention in transplant patients, offering a safer, better-tolerated alternative...- Roche Pharma India expands partnership with Cipla for key oncology medicinesRoche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distrib...
- Sun Pharma gets partial relief from US court in litigation involving three generic drugsDrug major Sun Pharma is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (Dist...
- Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patientsThe approved products is a generic therapeutic equivalent version of Roche's Valcyte.
- Aurobindo Pharma gets final USFDA nod for anti-viral drugAurobindo Pharma has received final approval from the US health regulator to manufacture and market anti-viral Valganciclovir tablets in th...
- Dr Reddy's Lab Q2 net rises 26% to Rs 722 croreSaumen Chakraborty, chief financial officer of Dr Reddy’s said, despite headwinds from a few segments, the company did well during the quar...
- India rejects Swiss drug maker Roche Patent claims on Valcyte againIndian authorities have for the second time rejected Swiss drug maker Roche’s patent claims on valganciclovir, or Valcyte, used to treat an...
- Ranbaxy loses approvals, exclusivity of two drugs in USIn November, Ranbaxy had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US.
- Dr Reddy's launches generic anti-viral tablets in US marketThe company launched Valganciclovir tablets, USP in the strength of 450 mg in the US market yesterday and the product has been approved by ...
- US court refuses Ranbaxy appeal to block ANDA nod for 2 drugsRanbaxy Laboratories had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US market.
- Dr Reddy's, Endo get FDA approval to launch generic ValcyteThe move comes after Ranbaxy said that FDA had stripped the company of its tentative approval to launch the first copy of the drug.
- Ranbaxy settles patent dispute with RocheDaiichi Sankyo-owned Ranbaxy Laboratories has settled its patent dispute with Swiss major Roche for the latter’s drug valganciclovir sold u...
- MSF welcomes India's decision to reject drug patent to Roche'Medicins Sans Frontieres', an international medical humanitarian group, today welcomed India's decision to reject a patent granted to Swis...
- SC asks Chennai patent office to hear RocheThe SC asked the Chennai patent office to hear and take a final view for all post-grant oppositions for a patent it had granted to Swiss co...
- SC asks Roche not to pursue Cipla case until patent examinationThe Supreme Court (SC) has asked Swiss company Roche not to pursue the patent violation case against the generic version of Cipla’s anti-in...
- Cipla opposes patent for GSK’s cancer drugCipla has filed a grant opposition in the Kolkata patent office against GSK's newly-launched breast cancer drug on grounds of obviousness a...
- HC breather for Roche in Cipla caseRoche has received a breather with the Bombay High Court granting company's request for an injunction against Cipla.
- Roche sues Cipla over Valcyte patent breachSwiss major Roche has moved the Bombay High Court (HC) against domestic major Cipla for allegedly infringing both the patent and trademark ...
- Delhi NGO opposes patent for Roche's HIV drugHIV patient group-Delhi Network of Positive People (DNP+)-has filed a post-grant opposition against Swiss major Roche’s patent for its HIV ...
- HIV drugs to cost more as cos rush for patentsHIV treatment in India could get costlier as global pharma cos have started securing patents for drugs used to treat AIDS and related disea...
Load More
